Metastases kill 90% of cancer patients. It is thus a major challenge in cancer therapy to inhibit the spreading of tumor cells from primary tumor sites to those particular organs where metastases are likely to occur. Whereas the actin cytoskeleton is a key component involved in cell migration, agents targeting actin dynamics have been relatively poorly investigated. Consequently, valuable in vitro pharmacological tools are needed to selectively identify this type of agent. In response to the absence of any standardized process, the present work aims to develop a multi-assay strategy for screening actin-affecting drugs with anti-migratory potentials. To validate our approach, we used two cancer cell lines (MCF7 and A549) and three actin-affecting drugs (cytochalasin D, latrunculin A, and jasplakinolide). We quantified the effects of these drugs on the kinetics of actin polymerization in tubes (by means of spectrofluorimetry) and on the dynamics of actin cytoskeletons within whole cells (by means of fluorescence microscopy). Using quantitative videomicroscopy, we investigated the actual effects of the drugs on cell motility. Finally, the combined drug effects on cell motility and cell growth were evaluated by means of a scratch-wound assay. While our results showed concordant drug-induced effects on actin polymerization occurring in vitro in test tubes and within whole cells, the whole cell assay appeared more sensitive than the tube assay. The inhibition of actin polymerization induced by cytochalasin D was paralleled by a decrease in cell motility for both cell types. In the case of jasplakinolide, which induces actin polymerization, while it significantly enhanced the locomotion of the A549 cells, it significantly inhibited that of the MCF-7 ones. All these effects were confirmed by means of the scratchwound assay except of the jasplakinolide-induced effects on MCF-7 cell motility. These later seemed compensated by an additional effect occurring during wound recolonization (possibly acting on the cell growth features). In conclusion, the use of multi-assays with different levels of sophistication and biological relevance is recommended in the screening of new actin-affecting drugs with potentially anti-migratory effects. D
Introduction
Cancer progression is a multi-step process that enables tumor cells to disperse to points far from a given primary tumor mass, and this often leads to metastasis. If detected in its early stage, solid cancer is often a locally circumscribed disease which can be treated successfully by the removal of the primary tumor. The mortality of more than 90% of cancer patients is not due to their primary tumors but to the development of metastases (Entschladen et al., 2004; Sporn, 1996) . Cell movement through tissue thus plays a crucial and primary role in cancer progression. This process requires a series of distinct but concerted biological events in which the actin cytoskeleton plays essential roles. These events include tumor cell attachment to the extracellular matrix (ECM) components, the degradation of the matrix by tumor cell-associated proteases, and tumor cell progression into the region where the matrix is modified by proteolysis (Kassis et al., 2001; Friedl and Wolf, 2003; Lefranc et al., 2005) .
Current anticancer treatments essentially target a tumor cell's ability to proliferate. However, many tumor cells are unaffected by this type of chemotherapy. Indeed, some cells are able to stay dormant for months, or even years, and to grow later into new tumors (Entschladen et al., 2004; Naumov et al., 2002) . Furthermore, migrating cells are known to show a decreased proliferation rate and are thus less sensitive to standard chemotherapy (Douma et al., 2004; Giese et al., 2003; Haga et al., 2003; Lefranc et al., 2005) . A major aim in modern cancer therapy strategies must therefore be to inhibit or, at least to reduce, the spreading of tumor cells by targeting the factors which regulate the migratory activity of these cells, and so to prevent metastasis. To decrease morbidity and mortality among cancer patients, therapeutic drugs that target cell motility and invasion may appear to be as important as drugs that restrict cell growth.
The targeting of cell motility and invasiveness in anticancer drug discovery has attracted increasing interest in recent years. This targeting essentially concerns extracellular activities leading to compounds that interfere with tumor adhesion to ECM components (Sawyer, 2004; Tucker, 2003) or reduce tumor-cell-associated protease activity (Zucker et al., 2000; Overall and Lopez-Otin, 2002; Coussens et al., 2002) . Unfortunately, none of these compounds have reached the market for various reasons such as poor in vivo antitumor activity, unsuitable therapeutic index, or the fact that tumor cells develop other mechanisms to overcome the activity of these drugs (Zucker et al., 2000; Friedl and Wolf, 2003) .
After studying the anti-migratory and anti-angiogenic properties of microtubule-affecting drugs (Hayot et al., 2002) , we focused our interest on the actin cytoskeleton, another essential actor in the cell locomotor apparatus. Therapeutic agents targeting actin dynamics have undergone relatively little investigation whereas actin dynamics plays essential roles in the spread of tumor cells and the endothelial cell migration leading to tumor vascularization (Jordan and Wilson, 1998; Fenteany and Zhu, 2003; Rao and Li, 2004) . However, no standardized strategy has been proposed for screening actin-affecting drugs with anti-migratory potentials. In response to this absence and the complexity of the cell migration process, the present work aims to develop an in vitro pharmacological strategy able to selectively identify such drugs and in which a distinction is made between the inhibition of cell motility and that of cell proliferation. We therefore tested anti-actin drugs for their ability to inhibit cell motility at concentrations associated with low (if any) cytotoxicity. To validate our approach, we used cytochalasin D, latrunculin A, and jasplakinolide. Cytochalasin D and latrunculin A are two potent inhibitors of actin polymerization. While cytochalasin D binds to the fast-growing plus ends of actin filaments and thus prevents the addition of actin monomers at those ends (Cooper, 1987) , latrunculin A forms 1:1 complexes with actin monomers and causes a disruption of the actin cytoskeleton in various cells (Coue et al., 1987; Spector et al., 1989) . Jasplakinolide is a recently discovered agent that also affects the actin cytoskeleton. While it has been shown in vitro that jasplakinolide induces actin polymerization (Bubb et al., 1994) , the data describing its effects on living cells show conflicting results with respect to concentrations and cell-type dependencies (Duncan et al., 1996; Senderowicz et al., 1995) .
In the present study, we adopted the following strategy. First of all, we employed spectrofluorimetry to monitor the in vitro effects of these drugs on the kinetics of actin polymerization in test tubes (Kouyama and Mihashi, 1981; Wieske et al., 2001) . Then, in order to test the effects of the drugs on living tumor cells, we first determined the cytotoxic concentrations of each one by means of the colorimetric MTT assay (Camby et al., 1996; Malonne et al., 2000) applied to the MCF7 breast and the A549 non-small cell lung cancer cell lines. Secondly, using computer-assisted fluorescence microscopy, we analyzed the effects of the drugs at non-cytotoxic concentrations on the dynamics of the actin cytoskeletons of these cells (Nagy et al., 2001; Hayot et al., 2002; Camby et al., 2002) . Finally, we completed our analyses by two distinct cell migration assays. While computer-assisted phase-contrast videomicroscopy was used to determine the migration levels of individual living cells (Hayot et al., 2002; De Hauwer et al., 1998) by means of a recently improved method (Debeir et al., , 2005 Lefranc et al., 2004) , a scratch-wound assay was used to characterize the combined drug effects on cell motility and cell growth features.
Materials and methods
Compounds. Cytochalasin D and latrunculin A were obtained from the Biomol Research Laboratories (PA, USA), and jasplakinolide from Molecular Probes (OR, USA). These compounds were dissolved in dimethylsulfoxide (DMSO) to yield stock solution at 1 mM.
Spectrofluorimetry for the determination of actin polymerization in vitro. We studied the effects of the 3 drugs on actin polymerization by means of a Perkin-Elmer LS-55 spectrofluorometer (Perkin-Elmer, CA, USA) equipped with a pulsed Xenon lamp and a temperature-controlled sample compartment under the overall control of the FL Winlab software (Perkin-Elmer, CA, USA). The test is based on the enhanced fluorescence of pyrene conjugated actin that occurs during polymerization. The enhanced fluorescence that occurs when pyrene G-actin (monomer) forms pyrene F-actin can be used to follow polymerization over time (Kouyama and Mihashi, 1981; Wieske et al., 2001 ). Fluorescence was monitored at an excitation wavelength of 360 nm (3 nm slit) and an emission wavelength of 407 nm (3 nm slit) for 1 h at 24 -C. Assay mixtures were prepared directly in a cuvette (Hellma cuvette 10 mm light path, Mü llheim, Germany) in a total volume of 1000 Al in the following manner. Labelled-actin (Cytoskeleton, CO, USA) at a final concentration of 0.052 mg/ml was equilibrated for 10 min at 24 -C in a spectrofluorometer. The drugs were then added and polymerization was started after 20 min by adding a salt solution (500 mM KCl, 20 mM MgCl 2 , 10 mM ATP in Tris-buffer pH 7.5). Under these conditions, the actin polymerization starts almost immediately. Each experiment was performed in triplicate and actin polymerization was analyzed over a period of 4000 s.
Cell lines and culture media. The MCF7 breast and the A549 non-small cell lung cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in vitro at 37 -C in sealed Falcon plastic dishes (Nunc, Gibco, Life Technologies, Belgium) containing Eagle's minimal essential medium (MEM, Gibco) supplemented with 5% fetal calf serum (FCS). All the media were supplemented with a mixture of 0.6 mg/ml glutamine (Gibco), 200 IU/ml penicillin (Gibco), 200 IU/ml streptomycin (Gibco), and 0.1 mg/ml gentamycin (Gibco). The FCS was heatinactivated for 1 h at 56 -C.
In vitro determination of global growth. As detailed previously (Camby et al., 1996; Malonne et al., 2000) , the cytotoxic effects of the 3 drugs (cytochalasin D, latrunculin A, and jasplakinolide) on the 2 tumor cell lines were determined by means of the colorimetric MTT assay on cells which had been incubated for 24 h in 96-microwell plates (at a concentration of 20,000 cells/ml culture medium) to ensure adequate plating prior to cell growth determination. The assessment of cell population growth is based on the ability of living cells to reduce the yellow reactive MTT [(3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, MO] to a blue product, formazan, by a reduction reaction occurring in the mitochondria of living cells. The number of living cells is directly proportional to the intensity of the blue staining which, in our case, was quantitatively measured by spectrophotometry on a Labsystems iEMS Reader MF (Labsystems, Helsinki, Finland) at a 570-nm wavelength (with a reference of 630 nm). Each experiment was carried out in sextuplicate.
Computer-assisted fluorescence microscopy for the in vitro determination of actin polymerization/depolymerization dynamics. The effects of the drugs on the actin assembly in the A549 and MCF7 cell lines were investigated by means of computer-assisted fluorescence microscopy, as detailed elsewhere (Nagy et al., 2001; Hayot et al., 2002; Camby et al., 2002) . Phallacidin conjugated with the greenfluorescent Alexa Fluor488 dye (Molecular Probes Inc., Eugene, Oregon) was used to label the fibrillar actin and Alexa Fluor594 conjugated DNAseI (Molecular Probes Inc.) to label the glomerular actin (Knowles and McCulloch, 1992) . Photographs of about 150 cells per experimental condition (performed in triplicate) were taken under the same carefully checked exposure conditions (for both fluorochromes) with a 100Â lens.
The fluorescent signals were quantified by means of a computer-assisted system using a PROVIS Olympus microscope (Omnilabo S.A., Antwerp, Belgium) coupled to a Megaview 2 camera (Omnilabo S.A.) feeding digitized information to a computer using the AnalySIS software (Soft Imaging System, GMbH, Munster, Germany).
Quantitative videomicroscopy for the determination of tumor cell migration. We used a prototype device able to quantitatively determine the migration features of living cells by means of a recently improved method (Debeir et al., , 2005 . These improvements aim to increase robustness (with respect to variability in cell morphologies and dynamic changes in cell shape during cell migration) and also to connect cell trajectories during mitoses in order to establish the migration potential of a cell through its genealogy, e.g., by measuring the distance covered by a cell and its successive cell generations (if the time available for observation allows). Living cells maintained in Falcon dishes containing a buffered medium are placed in a closed environment at a thermostat setting of 37.0 T 0.1 -C.
The cells are recorded via a CCD camera placed on a phase-contrast microscope. Specialized software has been developed to control this system and to analyze the data recorded (De Hauwer et al., 1998; Debeir et al., 2004 Debeir et al., , 2005 . Digitized images are recorded every 4 min to follow cell movement and development. In the present experiments, we recorded for 24 h the levels of migration of MCF7 and A549 cancer cells either treated by an actinaffecting drug, or left untreated. The drugs were added 30 min prior to the beginning of the cell tracking. Each experimental condition was run independently and in triplicate. Cell migration is determined by establishing the trajectory of each cell centroid (through cell divisions, see Debeir et al., 2005) . For each trajectory, the maximum relative distance from the origin (the quantitative MRDO variable) can be computed over the 24 h of observation. This variable refers to the greatest linear distance between a cell's original and subsequent positions normalized by the cell observation time (De Hauwer et al., 1998; Hayot et al., 2002; Debeir et al., 2004 Debeir et al., , 2005 .
Scratch-wound assay. In complement to quantitative videomicroscopy, the standard scratch-wound assay was used to investigate the combined drug effects on cell growth and migration (Coomber and Gotlieb, 1990; Zahm et al., 1997) . The A549 and MCF7 cells were plated onto six-well plates (at a concentration of 10 6 cells per well) and grown to confluence. Cell monolayers were carefully wounded by scratching with a sterile plastic pipette tip along the diameter of the well (as illustrated in the results). The cells were washed twice with PBS before their subsequent incubation with culture medium in the absence (control) or presence of cytochalasin D or jasplakinolide at appropriate concentrations. To follow wound colonization (involving both cell growth and cell migration) over time, five fields of each of the 3 wounds analyzed per condition were photographed 0, 8 h, 22 h, 31 h, and 49 h after the cell treatment. A software developed in our laboratory was used on the basis of these digital frames to quantify the area progressively filled by the cells over the period of the experiment.
Statistical analyses. We used non-parametric tests to compare the independent groups of numerical data because the conditions for applying the parametric tests were not satisfied. Statistical comparisons between multiple groups were made by first carrying out the Kruskal-Wallis test (a non-parametric one-way analysis of variance). In cases where this test revealed significant differences, we then investigated by means of the Mann-Whitney test whether any of the groups of treated cells differed from control.
Results

Influence of the actin-affecting drugs on actin polymerization in vitro
A spectrofluorometric assay was used to test the ability of each actin-affecting drug to affect actin polymerization in vitro. Three drug concentrations (10
À8
, 10 À6 , and 10 À5 M) were systematically employed. The degree of polymerization was monitored by measuring the fluorescent intensities of pyrene-actin versus time. These intensities were converted in terms of kinetic reaction velocities as shown in Fig. 1 , which presents the data obtained during the first 1000 s (during which the effects on actin polymerization occurred). Cytochalasin D inhibited actin polymerization from the lowest concentration used (i.e., 10 À8 M, see Fig. 1A ), while latrunculin A exhibited inhibitory effects at the higher concentrations only (10 À6 and 10 À5 M, see Fig. 1B ). Jasplakinolide induced actin polymerization at the different concentrations used (Fig.  1C) even before the addition of divalent cations, i.e., under nominally non-polymerizing conditions (data not shown).
Determination of IC 10 and IC 50 concentrations of the actin-affecting drugs
We characterized the effects of the three actin-affecting drugs on the overall growth patterns of the MCF7 breast cancer and the A549 lung cancer cell lines. The IC 10 and IC 50 values, i.e., the concentrations which reduced the overall growth value of each of the cell lines by 10% and 50%, respectively, are illustrated in Fig. 2 . These results (MCF7 in gray and A549 in black) show that cytochalasin D and latrunculin A exhibited lower cytotoxic profiles (IC 50 between 5Â10
À7 and 3Â10 À6 M) than jasplakinolide (i.e., IC 50 between 10 À9 and 5Â10 À8 M; Fig. 2A ). The evaluation of the IC 10 indices exacerbated these differences in the cytotoxicity observed in the A549 cells (Fig. 2B) . In view of the very similar profiles of cytochalasin D and latrunculin A shown in Figs. 1 and 2 , we continued our experiments on living cells with cytochalasin D and jasplakinolide only (these two drugs had very different effects). Since we wanted to test the effects of these drugs at non-cytotoxic concentrations, the concentrations used in the following experiments were selected as smaller or equal to the IC 10 index in each condition, i.e., at 10 À9 and 10 À8 M for cytochalasin D (on both the A549 and the MCF7 cells), 10 À15 and 10 À14 M for jasplakinolide on the A549 cells, and 5Â10 À11 and 5Â10 À10 M for jasplakinolide on the MCF7 cells (Fig. 2B) .
Influence of actin-affecting drugs on actin polymerization/depolymerization dynamics in tumor cells
As is illustrated by the graph in Fig. 3A and morphologically in Figs. 3C and D, cytochalasin D significantly decreased the F-actin/G-actin ratio observed in the A549 cells after 16 h of treatment. Untreated A549 cells (control, Fig. 3C ) had a basal F-actin/G-actin ratio about 40% above to the post-treatment ratio (Fig. 3D ). In the case of the MCF7 cells, cytochalasin D also significantly reduced the Factin/G-actin ratio after 16 h of treatment (Fig. 3I ) as compared to control (Fig. 3H) (Fig. 3F) . In agreement with the in vitro observations (Fig. 1C) , 16 h of jasplakinolide treatment produced entirely different effects on the two cell types. In the case of the A549 cells, it significantly increased the F-actin/G-actin ratio in a concentration-dependant way as compared to control (Figs. 3B, C, and E). A similar effect was observed on the MCF7 cells (as shown in Figs. 3G, H, and J). In conclusion, while the actin cytoskeletons of the A549 and MCF7 cells had completely different appearances (see Figs. 3C and H) , cytochalasin D reduced the actin polymerization and jasplakinolide clearly enhanced it in both cell types; this agreed with their effects as observed in vitro (Figs. 1A and C) .
Influence of actin-affecting drugs on cell migration
To characterize the specific effects of the drugs on cell migration, we used a time-lapse videomicroscopy system able to yield dynamic measurements of individual cell positions and applied to the observation of individual cells. From the initial cell positions indicated by the user (Fig.  4A) , the method is able to reconstitute individual cell trajectories over dozens of hours (Fig. 4B ). While Fig. 4B illustrates the trajectories obtained in an experiment carried out on the untreated A549 cells (control), Fig. 4C shows the cell trajectories obtained under cytochalasin D at 10 À8 M. These latter appeared shorter than those observed in control. In contrast, jasplakinolide (at 10 À14 M) increased the distance covered by the A549 cells (Fig. 4D) . These results were confirmed after quantification of the MRDO variable computed on 3 independent experiments (as shown in Figs. 4E-F). MRDO (Maximum Relative Distance from the point of Origin) characterizes each cell trajectory by computing the greatest linear distance covered by the cell between its initial position and the farthest position reached in its trajectory; this distance is in fact normalized by the observation period for the cell analyzed (in order to compare cell trajectories corresponding to possibly different tracking periods). Figs. 4E -H illustrate the quantitative results and evidence a significant decrease in the MRDO measured on both the A549 and MCF7 cells when treated with cytochalasin D (at least at the highest concentration, see Figs. 4E and G, respectively) . Jasplakinolide also evidenced inhibitory effects on the MCF7 cells at 5Â10 À11 M (Fig. 4H) . On the A549 cells, a very slight (though significant) inverse effect was observed at the highest concentration which was completely lost at the lowest concentration, i.e., under the corresponding IC 10 index (Fig. 4F) .
We completed our analysis by using the scratch-wound assay in order to characterize the combined effects of cytochalasin D and jasplakinolide on A549 and MCF7 cell migration and growth. The expansion of the cell population is quantified by calculating the percentage of recolonization of the wound surface over time. Figs. 5A and B illustrate an initial scratch wound carried out on a A549 cell culture (t = 0 h) and the colonization of the wound surface by these cells 31 h after their treatment with jasplakinolide at 10 of individual cell tracking except in the case of jasplakinolide on the MCF7 cells (see Fig. 4D ). In this latter case, the decrease in the levels of individual cell migration observed in Fig. 4D seemed compensated by an additional effect occurring during wound colonization, possibly acting at cell growth level (Fig. 5F ).
Discussion
Anticancer drug development strategies have traditionally focused on the direct inhibition of cancer cell growth. Angiogenesis and metastasis, other rate-limiting processes in the progression of cancer, are also promising targets for intervention. Cell shape changes and migration are involved in both processes. While the central intracellular ''motor'' of animal cell motility is actin cytoskeleton, the extracellular variables involved in cell migration are cell adhesion, ECM composition and the activity of matrix proteinases. Cell migration occurs by membrane protrusion (lamellipodia or filopodia), adhesion to ECM, cell body translocation, and tail retraction. All these processes imply actin dynamics, which is controlled by hundreds of proteins both inside and outside the cell (Fenteany and Zhu, 2003; Giganti and Friederich, 2003; Rao and Li, 2004) . There are several lanes of evidence showing that alterations in actin polymerization and remodeling appear in malignant cells; these alterations manifest themselves in the shape of altered cell morphology, altered cell adhesion and motility, disrupted cell division and apoptosis mechanisms (Giganti and Friederich, 2003; Rao and Li, 2004) . Invasion and metastasis inhibitors are effective (alone or in combination therapy with other agents) in restraining new tumor formation when earlier therapy or surgery has failed. Thus, proteins involved in cell motility are attractive targets for new chemotherapies (Fenteany and Zhu, 2003; Giganti and Friederich, 2003; Rao and Li, 2004) .
In cancer chemotherapy, a number of inhibitors of microtubule dynamics and function are already in use particularly for their blocking effects on mitosis and causing the apoptosis of dividing cells with interesting antiangiogenic consequences on tumor vasculature (immature or in the process of formation; Jordan and Wilson, 2004) . In addition to their role in cell division, microtubules have a supporting role in cell migration through direct and indirect interactions with actin that regulate processes such as the establishment and maintenance of cell polarity (Rodriguez et al., 2003; Etienne-Manneville, 2004) . This is why we previously studied the anti-migratory and anti-angiogenic properties of microtubule-affecting drugs and showed that, at non-cytotoxic concentrations, microtubule-affecting agents are able to significantly reduce the levels of migration of tumor cells; some of these effects may also occur via modifications to organization of the actin cytoskeleton (Hayot et al., 2002) . We also showed that, at non-cytotoxic concentrations, taxol, vincristine, and vindesine behave similarly in their ability to reduce the capillary network formation in HUVEC cells cultured on Matrigel. In contrast, vinblastine and vinorelbine produce apparent antiangiogenic effects by direct cytotoxicity (Hayot et al., 2002) . In contrast to microtubule-targeted agents, no actintargeted compounds are currently used in hospitals. These inhibitors would appear to have major side effects because different types of normal cells must also move to function and because actin is involved in a range of physiological processes (cytokinesis, exocytosis, endocytosis). More attractive targets seem to be the specific upstream components of the pathways of actin dynamics which are involved in cell motility, and especially those regulatory proteins that may play a larger role in diseased cells than in normal ones (Fenteany and Zhu, 2003; Giganti and Friederich, 2003; Rao and Li, 2004) . However, while the actin cytoskeleton itself is the direct target of a large and growing number of natural products, there is a lack of specific inhibitors for most of the proteins that regulate cytoskeleton dynamics, even though progress has recently been made in the discovery of new chemical probes. For instance, a serious campaign has been launched to develop ''intelligent drugs'' that target the Ras GTPase superfamily, which is a key element in controlling actin dynamics (Fenteany and Zhu, 2003; Giganti and Friederich, 2003; Rao and Li, 2004) .
However, pharmacological methodologies are needed to test the ability of drugs to target the cell locomotion mechanisms efficiently. The approach proposed in the present paper uses cell-free (in vitro) and cell-based assays to screen actin-affecting drugs. Whereas in vitro assays with pure actin, such as the one used in the present study, give quantitative and dynamic information on the effect of drugs on the actin polymerization, they do not take into consideration the complexity of the intracellular actin cytoskeleton dynamic. This is why we also introduced a cell-based assay to analyze the effects of the drugs on the cell actin cytoskeleton. This double-fluorescence labeling assay is used as a marker reflecting the status of actin remodeling in cells where the relative fluorescence intensities of F-and Gactin is measured. However, this latter assay does not inform about the impact of drug-induced actin remodeling on cell locomotion, i.e., the actual objective of any potentially antimigratory drug. To screen this impact on individual cell locomotion, we propose the use of a cell-tracking tool able to reconstruct individual cell trajectories over periods of long-term observation (Debeir et al., , 2005 . We completed our analysis by the use of a scratch-wound assay in which both cell motility and cell growth are involved. Our approach distinguished between cell motility and the inhibition of cell proliferation by testing drugs for their ability to inhibit cell motility at concentrations associated with low cytotoxicity, if any at all. We illustrated our methodology on different members of the two major categories of compounds targeting actin directly. The first category, to which cytochalasin D and latrunculin A belong, groups actin polymerization inhibitors by capping filaments binding to monomers and/or by disrupting the filaments. The second category, to which jasplakinolide belongs, concerns the inductor of actin polymerization. However, while jasplakinolide is able to stimulate actin polymerization (Bubb et al., 1994 (Bubb et al., , 2000 , it can also disrupt F-actin fibers with alterations in cellular architecture (Senderowicz et al., 1995; Spector et al., 1999) , possibly by blocking the FAK signal pathway (Duncan et al., 1996) . However, our results displayed concordant jasplakinolide-induced actin polymerization enhancing effects both in vitro and within two different tumor cell types (A549 and MCF7 cells) which exhibited completely different actin cytoskeleton morphologies characterized by different basal F-actin/Gactin ratios (see Fig. 3 ). This contrasted with the inhibitor effects evidenced in the case of cytochalasin D (in vitro and within cells). The similar effects induced by cytochalasin D on the actin cytoskeletons of the two cell types were paralleled by a decrease in cell motility and wound colonization. In contrast, the jasplakinolide-induced effects on cell migration differed according to the assay used. Indeed, the analysis of individual cell trajectories by means of quantitative videomicroscopy evidenced that while jasplakinolide significantly enhanced the locomotion of the A549 cells (at the highest concentration), it significantly inhibited that of the MCF-7 cells (at the lowest concentration). The use of a scratch-wound assay suggested that this latter inhibition could be compensated by an additional effect (possibly acting at cell growth level). Consequently, this assay evidenced more similar jasplakinolide-induced effects on the two cell lines (although the effects on the MCF-7 cells were not statistically significant). All these results justify the need to use complementary assays with increasing levels of sophistication and biological relevance in order to test the anti-migratory properties of actin-targeted compounds. Intriguingly, while the effects of jasplakinolide on the polymerization of pure or intra-cell actin have been relatively well documented (as mentioned above), very few data are available on its effects on cell motility. Indeed, the sole data available (at least to our knowledge) concern the inhibition of motility of the bacterium Listeria and of fibroblasts (Cramer, 1999) . This effect occurred at a concentration of 10 À6 M, which was evidenced as being highly toxic in the case of both A549 and MCF7 cells (see Fig. 2 ). The inhibiting effects of cytochalasin D on cell motility have been reported in accordance with our results in the case of different cells types such as hepatic cells (Amakawa and Endo, 2002) , smooth muscle cell (Bruijns and Bult, 2001) , and tumor cells (Stracke et al., 1993; Verschueren et al., 1995) .
In conclusion, tumor cell locomotion is a complex process. The use of multi-assay strategies is therefore usually recommended to obtain maximum benefit from the screening of actin-targeted drugs with a view to identifying potentially anti-migratory compounds.
